Long-term effect of the beta2-receptor agonist procaterol on daily life performance and exercise capacity in patients with stable chronic obstructive pulmonary disease. Clinical study with special reference to health-related quality of life and activities of daily living.
The present study was undertaken to evaluate the long-term effect of procaterol hydrochloride (CAS 62929-91-3, Meptin), a third generation beta2-receptor agonist on lung function, exercise capacity, health-related quality of life (HRQOL) and activities of daily living (ALDs) in patients with stable chronic obstructive pulmonary disease (COPD). Twenty patients were randomly assigned to the procaterol group or to the control group, who received oxitropium bromide (CAS 30286-75-0), an anticholinergic agent. Procaterol was inhaled three times a day at a dose of 20 pg, while oxitropium was inhaled three times a day at a dose of 200 microg. The subjects were evaluated based on spirometry, exercise capacity, the Borg Scale, HRQOL, and ADLs before and after 12, 24 and 52 weeks of therapy. The values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV), maximal inspiratory pressure (PImax), and maximal expiratory pressure (PEmax) were significantly improved at 12, 24 and 52 weeks compared with baseline values in the procaterol group (p < 0.05, p < 0.01), while these values did not differ from baseline values at any point in the oxitropium group (p > 0.05). Additionally, 6-min walking distances and Borg Scale values showed significant improvement at 12, 24 and 52 weeks compared with baseline values in the procaterol group (p < 0.05, p < 0.01), but did not significantly differ from baseline values in the oxitropium group at any point (p > 0.05). Likewise, the scores for dyspnea, fatigue, emotional function, mastery, total scores and ADLs were significantly higher at 12, 24 and 52 weeks compared with the baseline values in the procaterol group (p < 0.05, p < 0.01), but did not differ at any point in the oxitropium group (p > 0.05). These results suggest the effectiveness of long-term regular bronchodilator therapy with the beta2-receptor agonist procaterol in patients with stable COPD.
Shioya
Takanobu
T
Department of Physical Therapy, Akita University School of Health Sciences, Akita, Japan. shioya@hos.akita-u.ac.jp
Satake
Masahiro
M
Sato
Kazuhiro
K
Sano
Masa-aki
MA
Sugawara
Keiyu
K
Takahashi
Hitomi
H
Honma
Mitsunobu
M
D000203:Activities of Daily Living / Q000523:psychology*; D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D000368:Aged; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use; D017265:Procaterol / Q000009:adverse effects* / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D011788:Quality of Life / Q000523:psychology*; D012129:Respiratory Function Tests; D012602:Scopolamine Derivatives / Q000627:therapeutic use; D013147:Spirometry; D011795:Surveys and Questionnaires
D000318:Adrenergic beta-Agonists; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C017590:oxitropium; D017265:Procaterol